Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC
TAP-ALK: A Phase I/II Study of TNG462 in Combination With Lorlatinib in MTAP-Deleted, ALK-Rearranged NSCLC Following Progression on Prior TKI Therapy
TAP-ALK is a DF/HCC investigator-sponsored interventional study of TNG462 (vopimetostat) in combination with lorlatinib for participants with MTAP-deleted, ALK-rearranged non-small cell lung cancer (NSCLC) following progression on prior tyrosine kinase inhibitor (TKI) therapy. The study is being conducted under IND 183798 and plans to enroll 30 participants.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This study evaluates a treatment regimen combining TNG462 and lorlatinib, both administered once daily per the consent study plan. Baseline assessments are performed before registration, with protocol-specified on-treatment visits during Cycle 1, Cycle 2, and subsequent cycles. Scheduled evaluations include physical examinations, vital signs, weight, performance status, laboratory testing, ECGs, adverse event review, and tumor measurements. Tumor imaging is repeated every 2 cycles for the first 6 months, then every 3 cycles thereafter. The consent form also describes optional tumor biopsies and optional plasma/serum collections for research.
For the Phase I portion, the protocol states that a BF-BOIN dose-escalation and backfilling design will be used, with no formal stratification factors applied to dose-escalation decisions.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Alice Shaw, MD, PhD
- Número de telefone: 617-632-5301
- E-mail: alice_shaw@dfci.harvard.edu
Locais de estudo
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana Farber Cancer Institute
-
Investigador principal:
- Alice Shaw, MD, PhD
-
Contato:
- Alice Shaw, MD, PhD
- Número de telefone: 617-632-5301
- E-mail: alice_shaw@dfci.harvard.edu
-
Boston, Massachusetts, Estados Unidos, 02215
- Brigham and Women's Hospital
-
Investigador principal:
- Alice Shaw, MD, PhD
-
Contato:
- Alice Shaw, MD, PhD
- Número de telefone: 617-632-5301
- E-mail: alice_shaw@dfci.harvard.edu
-
Contato:
- Número de telefone: 617-632-5301
- E-mail: alice_shaw@dfci.harvard.edu
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age ≥ 18 years
-
Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test.
-
Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal control, or homozygous deletion by next-generation sequencing (NGS) in a CLIA-/ISO-accredited laboratory. The Sponsor-Investigator will review molecular testing to confirm eligibility (central reading of the IHC sample and/or repeat MTAP staining on archival tissue; check of the NGS report). Cases with heterogenous MTAP loss in IHC defined as MTAP loss in at least 80% of the tumor cells but less than 100%, may be included with the permission of the Sponsor-Investigator and after central revision of the slides.
-
Radiographic disease progression after at least one or more ALK TKIs, including prior lorlatinib therapy. Prior chemotherapy and prior neladalkib (NVL-655) are allowed
-
At least one measurable extracranial lesion according to RECIST v1.1.
-
ECOG performance status 0-1 (Appendix A). ECOG performance status 2 may be allowed with the permission of the Sponsor-Investigator
-
Adequate organ and marrow function, defined as:
- ANC ≥ 1.5 × 10⁹/L
- Platelets ≥ 75 × 10⁹/L, without platelet transfusion within 7 days prior to screening hematology assessment
- Hemoglobin > 8.5 g/dL without transfusion within 14 days prior to screening hematology assessment
- AST/ALT ≤ 2.5 × ULN (≤ 5 × ULN with documented liver metastases)
- Total bilirubin ≤ 1.5 × ULN
- Creatinine clearance ≥ 45 mL/min
-
Stable, previously treated brain metastases permitted if neurologically stable ≥ 2 weeks and on ≤ 10 mg prednisone equivalent. Untreated CNS metastases may be permitted with PI approval if: lesions are asymptomatic, ≤5 mm in size, no radiologic evidence of surrounding edema, and no current or anticipated need for corticosteroids.
-
Life expectancy ≥ 12 weeks.
-
Ability to swallow oral medication. TNG 462 tablets may be crushed and administered via NG-G tube if necessary, with written approval from Principal Investigator. Lorlatinib may not be crushed.
-
Written informed consent obtained prior to study procedures.
-
Participants must understand, sign and date the written informed consent form prior to any protocol-specific procedures performed. Participants should be able and willing to comply with study visits and procedures as per protocol
Exclusion Criteria:
- 3.2.1 Prior treatment with a PRMT5 inhibitor, MAT2A inhibitor, or any investigational agent targeting the same pathway.
3.2.2 Prior treatment with lorlatinib resulting in discontinuation due to ≥ Grade 3 toxicity or with unresolved ≥ Grade 2 neurocognitive, pulmonary, or psychiatric adverse events at screening.
3.2.3 Ongoing or unresolved toxicity > Grade 1 from previous anticancer therapy (per CTCAE v5.0), except for the following: alopecia, endocrinopathies controlled by replacement therapy, or other protocol-allowed persistent Grade 2 toxicities (e.g., neuropathy) that, in the investigator's judgment, do not pose an unacceptable safety risk.
3.2.4 Major surgery within 4 weeks before first dose or incomplete recovery from surgery
3.2.5 Radiotherapy within 2 weeks before C1D1 (≤ 1 week for palliative RT ≤ 2 Gy/fraction); prior cranial RT permitted if completed ≥ 2 weeks before C1D1 and participant neurologically stable.
3.2.6 Concomitant use of strong or moderate CYP3A inhibitors or inducers, CYP3A or P-gp substrates with a narrow therapeutic index (e.g., digoxin, cyclosporine), or OATP1B3 substrates with a narrow therapeutic index (e.g. rosuvastatin, methotrexate, sirolimus), that cannot be discontinued or replaced.
3.2.7 Use of medications known to prolong QTc > 480 ms that cannot be safely discontinued.
- Leptomeningeal carcinomatosis or spinal cord compression unless treated, clinically stable ≥ 4 weeks, and off steroids ≥ 14 days.
- History of seizure disorder requiring enzyme-inducing antiepileptic drugs that cannot be substituted.
- Baseline QTc > 480 ms (Fridericia), PR > 220 ms, clinically significant atrioventricular (AV) block, or uncontrolled arrhythmia.
- History of myocardial infarction, unstable angina, coronary revascularization, stroke, or transient ischemic attack (TIA) within 6 months before C1D1.
- Symptomatic congestive heart failure (NYHA ≥ Class II) or uncontrolled hypertension despite optimal medical therapy.
- Interstitial lung disease, organizing pneumonia, or drug-induced pneumonitis, including prior lorlatinib-related pneumonitis, unless completely resolved.
- Known HBsAg-positive or HCV RNA-positive infection with detectable viral load. Participant on suppressive antiviral therapy with undetectable viremia are eligible.
- HIV infection with CD4 < 200/μL or on antiretrovirals that are strong CYP3A modulators.
- Active uncontrolled infection requiring intravenous therapy within 7 days before C1D1.
- Clinically significant gastrointestinal disorder that may affect absorption of oral medications (e.g., malabsorption syndrome, chronic diarrhea, short-bowel syndrome).
- Uncontrolled hyperlipidemia defined as fasting total cholesterol > 300 mg/dL or triglycerides > 300 mg/dL despite medical management.
- Clinically significant neurocognitive disorder, mood alteration, or psychiatric illness (including major depression or psychosis) that, in the investigator's judgment, could be exacerbated by lorlatinib or impair adherence.
- Any other active malignancy within 2 years prior to enrollment, except adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, early-stage prostate cancer undergoing active surveillance, curatively treated thyroid cancer, early stage breast cancer or DCIS, or any in situ cancers that have been treated with curative intent.
- Pregnancy or breastfeeding. Women of childbearing potential must have a negative serum pregnancy test within 7 days before first dose and agree to use two highly effective contraceptive methods during treatment and for ≥ 6 months after the last dose. Male participants must use effective contraception for ≥ 3 months after the last dose.
- Known hypersensitivity to TNG462, lorlatinib, or any of their excipients.
- Has any of the following: prior history of drug-induced or toxic retinopathy, or optic neuropathy; uncontrolled glaucoma; pre-existing macular degeneration; ongoing Grade ≥3 retinopathy, optic neuropathy, or optic neuritis; or any other known active retinal pathology.
- Any condition (medical, psychiatric, social, or laboratory abnormality) that, in the opinion of the investigator, may confound study results, increase risk, or interfere with study compliance.
- Participants who, in the investigator's or Sponsor-Investigator's judgment, are unable to comply with protocol requirements or whose participation would not be in their best interest may be excluded.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: TNG462 plus Lorlatinib
Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar. |
Investigational drug Supplier/manufacturer: Tango Therapeutics
Outros nomes:
Source/manufacturer: Commercial supply / Pfizer |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
Prazo: Up to 28 days.
|
A DLT is defined as a treatment-emergent adverse event occurring during Cycle 1 that is considered at least possibly related to TNG462, lorlatinib, or the combination and is not clearly attributable to underlying disease, intercurrent illness, or concomitant medications. DLTs include Grade ≥3 non-hematologic toxicities with specified exceptions for transient or manageable events; clinically significant hepatic, pulmonary, pancreatic, cardiac, ECG, CNS, or neurocognitive toxicities; Grade 4 hematologic toxicities; Grade ≥3 febrile neutropenia; Grade ≥3 thrombocytopenia with clinically significant bleeding; prolonged treatment-related hematologic toxicity requiring interruption of both study drugs for >14 consecutive days; any toxicity resulting in permanent discontinuation of both study drugs during Cycle 1 due to safety concerns; and any death at least possibly related to study treatment during the DLT assessment period. |
Up to 28 days.
|
|
Maximum Tolerated Dose (MTD) of TNG462
Prazo: Up to 28 days.
|
The study uses a Backfill Bayesian Optimal Interval (BF-BOIN) design to determine the MTD of TNG462. TNG462 will start at 200 mg QD and may be escalated to 250 mg QD at the optional Dose Level 3 if Dose Level 2 is tolerated, at the discretion of the Sponsor-Investigator. |
Up to 28 days.
|
|
MTD of Lorlatinib
Prazo: Up to 28 days.
|
The study uses a BF-BOIN design to determine the MTD of Lorlatinib. Lorlatinib will start at 50 mg QD and may be escalated to 75 mg QD at Dose Level 2 if Dose Level 1 is tolerated. Lorlatinib will remain at 75 mg QD at the optional Dose Level 3. |
Up to 28 days.
|
|
Recommended Phase II Dose (RP2D) of TNG462 in Combination with Lorlatinib
Prazo: Up to 28 days.
|
The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I. |
Up to 28 days.
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective response rate (ORR)
Prazo: Tumor measurements are repeated every 2 cycles for the first 6 months and every 3 cycles thereafter.
|
The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I. ORR is defined as the proportion of patients achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. |
Tumor measurements are repeated every 2 cycles for the first 6 months and every 3 cycles thereafter.
|
|
Duration of Overall Response (DOR)
Prazo: From date of first documented CR/PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
DOR based on Kaplan-Meier method is defined as the time from the first documented CR or PR until documented disease progression or death from any cause, whichever occurs first. Participants without disease progression or death will be censored at the date of their last disease evaluation. |
From date of first documented CR/PR until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Median progression-free survival (PFS)
Prazo: From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
PFS based on Kaplan-Meier method is defined as the time from registration to progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. |
From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
PFS Rate at 6 Months (PFS6)
Prazo: Up to 6 months.
|
PFS6 rate is defined as the proportion of evaluable participants who are alive and free of documented disease progression at 6 months after registration. articipants with documented disease progression or death from any cause before 6 months are considered non-responders. Participants who withdraw, are lost to follow-up, or lack adequate disease assessment before 6 months will be considered non-evaluable. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. |
Up to 6 months.
|
|
Median Time to Treatment Failure (TTF)
Prazo: From date of registration until the date of first documented progression or date of death from any cause or permanent discontinuation of protocol therapy, or initiation of new cancer therapy, whichever came first, assessed up to 24 months
|
TTF based on the Kaplan-Meier method is defined as the time from registration to documented disease progression, death from any cause, permanent discontinuation of protocol therapy for toxicity or any other reason, or initiation of new systemic anticancer therapy, whichever occurs first. Participants who remain on protocol therapy without any of these events is censored at the date of their last protocol treatment administration. |
From date of registration until the date of first documented progression or date of death from any cause or permanent discontinuation of protocol therapy, or initiation of new cancer therapy, whichever came first, assessed up to 24 months
|
|
Median Overall Survival (OS)
Prazo: From date of treatment initiation until the date of death from any cause, assessed up to 24 months
|
OS based on Kaplan-Meier method is defined as the time from treatment initiation until death due to any cause; participants who are alive at the time of analysis will be censored at the time of their last follow up. |
From date of treatment initiation until the date of death from any cause, assessed up to 24 months
|
|
Central Nervous System (CNS)-Specific PFS
Prazo: From date of registration until the date of first documented intracranial progression or date of death from any cause, whichever came first, assessed up to 24 months
|
CNS-specific PFS based on Kaplan-Meier method is defined as the time from registration to the first documented intracranial disease progression or death from any cause, whichever occurs first. Intracranial progression is defined as progression of existing CNS lesions or the appearance of new CNS lesions according to RECIST v1.1 applied to CNS disease, as assessed by the investigator using protocol-mandated brain MRI. Participants without an event will be censored at the date of their last adequate CNS imaging assessment. Participants with extracranial-only progression will be censored at the date of their last CNS assessment. |
From date of registration until the date of first documented intracranial progression or date of death from any cause, whichever came first, assessed up to 24 months
|
|
Trough Concentrations of TNG462 and Lorlatinib
Prazo: At day 22.
|
Trough concentrations are defined as the measured plasma concentrations of TNG462 and lorlatinib. |
At day 22.
|
|
Central Nervous System (CNS) Adverse Event Rate
Prazo: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
CNS-AE Rate is defined as the proportion of participants who experience a CNS adverse event. AEs are graded based on CTCAE v5.0. |
AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
|
Hypercholesterolemia Rate
Prazo: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
Hypercholesterolemia rate is defined as the proportion of participants who experience hypercholesterolemia. AEs are graded based on CTCAE v5.0. |
AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
|
Hypertriglyceridemia Rate
Prazo: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
Hypertriglyceridemia rate is defined as the proportion of participants who experience hypertriglyceridemia. AEs are graded based on CTCAE v5.0. |
AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
|
Hepatotoxicity Rate
Prazo: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
Hepatotoxicity rate is defined as the proportion of participants who experience hepatotoxicity. AEs are graded based on CTCAE v5.0. |
AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
|
Interstitial Lung Disease or Pneumonitis Rate
Prazo: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
Interstitial lung disease or pneumonitis rate is defined as the proportion of participants who experience interstitial lung disease or pneumonitis. AEs are graded based on CTCAE v5.0. |
AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
|
Hematologic Toxicity Rate
Prazo: AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
Hematologic toxicity rate is defined as the proportion of participants who experience a hematologic toxicity. AEs are graded based on CTCAE v5.0. |
AEs are collected until 30 days post treatment discontinuation, assessed up to 24 months
|
|
Change from Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Physical functioning is assessed using EORTC QLQ-C30. The physical functioning scale consists of 5 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better physical functioning. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Role Functioning Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Role functioning is assessed using the EORTC QLQ-C30. The role functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better role functioning. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Emotional Functioning Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Emotional functioning is assessed using the EORTC QLQ-C30. The emotional functioning scale consists of 4 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better emotional functioning. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Cognitive Functioning Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Cognitive functioning is assessed using the EORTC QLQ-C30. The cognitive functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better cognitive functioning. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Social Functioning Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Social functioning is assessed using the EORTC QLQ-C30. The social functioning scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better social functioning. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Global Health Status/Quality of Life Scores (QoL)
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Global health status/QoL is assessed using the EORTC QLQ-C30. The global health status/QoL scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating better global health status and quality of life. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Fatigue Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Fatigue is assessed using the EORTC QLQ-C30. The fatigue scale consists of 3 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater fatigue. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Nausea and Vomiting Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Nausea and vomiting are assessed using the EORTC QLQ-C30. The nausea and vomiting scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater nausea and vomiting. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Pain Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Pain is assessed using the EORTC QLQ-C30. The pain scale consists of 2 items. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater pain. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Dyspnea Score
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Dyspnea is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater dyspnea. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Insomnia Score
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Insomnia is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater insomnia. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Appetite Loss Score
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Appetite loss is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater appetite loss. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Constipation Score
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Constipation is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater constipation. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Diarrhea Score
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Diarrhea is assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater diarrhea. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change from Baseline in EORTC QLQ-C30 Financial Difficulties Score
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Financial difficulties are assessed using the EORTC QLQ-C30 as a single item. The score is calculated according to the EORTC QLQ-C30 scoring manual and linearly transformed to a 0-100 scale, with higher scores indicating greater financial difficulties. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
|
Change From Baseline in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) Scores
Prazo: Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
The EORTC QLQ-LC13 is a 13-item lung cancer-specific questionnaire comprising symptom scales and single items. Each scale and item score is transformed to a range of 0 to 100, with higher scores indicating greater symptom burden. |
Assessed at baseline and every 8 weeks on treatment, assessed up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Alice Shaw, MD, PhD, Dana-Farber Cancer Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 26-561
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
The Harvard Cancer Consortium encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
Prazo de Compartilhamento de IPD
Data can be shared no earlier than 1 year following the date of publication
Critérios de acesso de compartilhamento IPD
DFCI- Contact the Belfer office for Dana -Farber Innovations (BODFI) at innovations@dfci.harvard.edu
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .